

NEW DIRECTIONS IN LEUKAEMIA RESEARCH

2 - 4 March, 2026
Adelaide Convention Centre
Adelaide, South Australia

PROGRAM

Start Time	End Time	Paper #	Room
------------	----------	---------	------

SUNDAY 1 MARCH 2026

08:00	18:00	Exhibition booth build and exhibitor move-in.	HALL M
15:00	18:00	Speaker Support	Room L2

MONDAY 2 MARCH 2026

07:30	18:00	Registration Opens	FOYER M
07:30	18:00	Exhibition & Poster Displays Open	HALL M
08:00	16:00	Speaker Support	Room L2

9:00 10:55 CONFERENCE OPENING & SESSION 1 - Myeloproliferative Neoplasms HALL L

CHAIRS: Dr Megan Bywater and Dr Sebastien Malinge

9:00	9:05	Welcome and Conference Opening	
9:05	9:25	INVITED SPEAKER: Anna Steiner (MPN), Consumer Representative & Advocate in Blood Cancer Research	
9:25	9:55	INVITED SPEAKER: Targeting Menin in the Myeloproliferative Neoplasms Professor John Crispino , St. Jude Children's Research Hospital	
9:55	10:25	INVITED SPEAKER: Ironing out PV disease Dr Cavan Bennett , Walter and Eliza Hall Institute of Medical Research	
10:25	10:40	17 From Mutation to Transformation: Acquired Mutations Transcriptionally Reprogram Haematopoietic Stem Cells to Drive MPN and Post-MPN AML, Dr Jasmin Straube, QIMR Berghofer	
10:40	10:55	89 Ultra-Precision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting in a Humanised Niche Model of Myelofibrosis, Dr Chloe Thompson-Peach, Adelaide University	

10:55 11:25 Morning Tea & Trade Display HALL M

11:25 12:40 SESSION 2 - Bone Marrow Microenvironment/Spatial Profiling HALL L

CHAIRS: Dr Jasmin Straube and Dr Ashwin Unnikrishnan

11:25	11:55	INVITED SPEAKER: Spatial transcriptomic profiling of the bone marrow microenvironment in multiple myeloma, Dr Raymond Yip , Walter and Eliza Hall Institute of Medical Research	
11:55	12:10	30 The spatial organisation of the paediatric AML bone marrow, Prof. Dr. Olaf Heidenreich, Princess Maxima Center For Pediatric Oncology	
12:10	12:25	58 Uncovering the in vivo dynamics of blood cancer cell death and clearance in the bone marrow microenvironment post-therapy, Dr Georgia Atkin-Smith, WEHI	
12:25	12:40	96 Investigating ribosome-targeting therapies for the treatment of relapsed/ refractory multiple myeloma, A/Prof Elaine Sanij, St Vincent's Institute of Medical Research	

12:40 13:40 Lunch & Trade Display HALL M

PROGRAM

Start Time	End Time	Paper #	Room
------------	----------	---------	------

MONDAY 2 MARCH 2026 (CONTINUED)

13:40	14:40	SESSION 3 - Equity and Diversity in Sponsorship/Mentorship	HALL L
13:40	14:00	Equitable access to mentorship and sponsorship for EMCRs, A/Prof Edwin Hawkins, WEHI	
14:00	14:20	Equitable access to mentorship and sponsorship from consumer perspective, Sarah Lukeman, Consumer Representative	
14:20	14:40	Panel Discussion and Q&A: A/Prof Edwin Hawkins, WEHI, Sarah Lukeman, Consumer Representative, Prof Gemma Kelly, WEHI, Dr Cedric Tremblay, CancerCare Manitoba Research Institute	
14:40	15:00	Rapid Fire Presentations 1	
		<i>CHAIR: Dr Donia Moujalled</i>	
		11 Therapy-induced mechanisms of adaptive resistance in T-cell Acute Lymphoblastic Leukaemia, Johnathon Lucas, University of Manitoba	
		22 Multi-Omic Profiling to Inform AML Treatment Strategies, Dr Heather Murray, The University of Newcastle	
		28 Defining the non-catalytic role of NSD2 in t(4;14) Multiple Myeloma, Mr Joshua King, Peter MacCallum Cancer Centre	
		54 Harnessing the gut-brain axis to reduce CNS toxicity in acute lymphoblastic leukaemia, Dr Elyse Page, SAHMRI	
		70 Distinct signalling networks and drug responses of JAK2 and NRAS mutant subclones in CRLF2-positive B-ALL, Ms Kaitlyn Kew, Olivia Newton John Cancer Research Institute	
15:00	15:30	Afternoon Tea & Trade Display	HALL M
15:30	17:05	SESSION 4 - Myeloma	HALL L
		<i>CHAIRS: Prof Jake Shortt and Dr Melissa Cantley</i>	
15:30	15:50	INVITED SPEAKER: CAR-T therapy in myeloma - a new era, Professor Joy Ho (Clinical Spotlight), The University of Sydney	
15:50	16:20	INVITED SPEAKER: Preclinical optimization of T cell redirected therapy against multiple myeloma, Associate Professor Marta Chesi , Mayo Clinic <i>sponsored by:</i> THE BARRIE DALGLEISH CENTRE <small>for Myeloma & Related Blood Cancers</small>	
16:20	16:50	INVITED SPEAKER: Targeting the aberrant epigenetic landscape of multiple myeloma Associate Professor Lev Kats , Peter MacCallum Cancer Centre	
16:50	17:05	43 CRISPR-Cas9-based functional genomic screening reveals the heme biosynthesis enzyme ALAD as a critical dependency for multiple myeloma tumour growth in vivo, Dr Emma Cheney, Adelaide University	
17:05	17:25	Rapid Fire Presentations 2	
		<i>CHAIR: Dr Elise Page</i>	
		42 Using Olink proteomics and single RNA sequencing to discover proteins that distinguish MGUS and multiple myeloma., Dr Melissa Cantley, Adelaide University	
		52 Inhibition of nicotinamide metabolism by the novel NAMPT inhibitor OT-82 potentiates venetoclax in paediatric and adult acute myeloid leukaemia models, Mawar Karsa, Children's Cancer Institute	
		31 Stag2 cohesin loss promotes myelodysplasia and leukaemia through chromatin regulation, Dr Jane Xu, Columbia University Irving Medical Center	
		64 Unravelling the epigenetic drivers of CHIP – MDS/CMML – AML progression through novel Methylation-Sensitive Regulatory Elements, Dr Mahmoud Bassal, Beth Israel Deaconess Medical Center	
		87 RAS pathway-mutant acute myeloid leukaemia is resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF antibody therapy, Kelly Lim, Adelaide University	
17:30	19:30	Welcome Reception & Poster Session	HALL M

PROGRAM

Start Time	End Time	Paper #	Room
------------	----------	---------	------

TUESDAY 3 MARCH 2026

07:00	18:00	Registration Opens	FOYER M
08:00	18:00	Exhibition & Poster Displays Open	HALL M
08:00	16:00	Speaker Support	Room L2
07:30	08:45	Breakfast Session - Meet the Experts	GILBERT SUITE
9:00	11:00	SESSION 5 - Acute Lymphoblastic Leukaemia <i>sponsored by:</i> 	HALL L
		<i>CHAIRS: Dr Hansen Kosasih and Dr Laura Eadie</i>	
9:00	9:30	INVITED SPEAKER: Transcriptional dysregulation in T-ALL Professor Jan Cools , HemaSphere	
9:30	10:00	INVITED SPEAKER: Omics-enabled strategies for molecular and functional profiling in ALL, Associate Professor Jessica Nordlund , Uppsala University	
10:00	10:30	INVITED SPEAKER: Molecularly diagnosing leukaemia in the ZERO Childhood Cancer Program, Dr Chelsea Mayoh , Children's Cancer Institute	
10:30	10:45	62 Decitabine-Based Therapy Reshapes Glucocorticoid Response in Pediatric ETP-ALL with Extent of Benefit Predicted by Epigenetic Features, Dr Yizhou Huang , Children's Cancer Institute	
10:45	11:00	9 Defining chemotherapy-induced stress response in T-cell Acute Lymphoblastic Leukemia, Ovini Amarasinghe , University of Manitoba	
11:00	11:30	Morning Tea & Trade Display	HALL M
11:30	12:50	SESSION 6 - Lymphoma <i>sponsored by:</i> 	HALL L
		<i>CHAIRS: Prof Gemma Kelly and Prof Daniel Thomas</i>	
11:30	11:50	INVITED SPEAKER: Novel immunotherapies for B-cell lymphoma-do we know what we don't know?, Professor Eliza Hawkes (Clinical Spotlight), Olivia Newton John Cancer Research Institute at Austin Health	
11:50	12:20	INVITED SPEAKER: Pathogenesis and therapy of immune system neoplasms Professor Ari Melnick , Weill Cornell Medicine College	
12:20	12:35	51 SOX11-induced reprogramming of B2 cells to a B1a-like phenotype promotes Mantle Cell Lymphoma in mice , Dr Tim Pieters , Ghent University	
12:35	12:50	103 Defining DDX3Y as a synthetic lethal target in DDX3X-mutated B-cell lymphomas, Dr Sam Greenall , Monash University	

PROGRAM

Start Time	End Time	Paper #	Room
------------	----------	---------	------

TUESDAY 3 MARCH 2026 (CONTINUED)

12:50	13:50	Lunch & Trade Display	HALL M
-------	-------	-----------------------	--------

13:50	14:45	SESSION 7 - Metcalf Oration	HALL L
-------	-------	-----------------------------	--------

CHAIRS: A/Prof Charles de Bock

13:50 14:00 Metcalf Introduction - Associate Professor Charley de Bock

14:00 14:45 **MetCalf Oration** - Professor Richard Lock

14:45	15:45	SESSION 8 - New Investigator Event - Consumer Engagement and Involvement in Research	HALL L
-------	-------	--	--------

14:45 14:55 **Introduction:** Dr Lauren Thurgood, Dr Ashwin Unnikrishnan

14:55 15:00 **Consumer Introduction**

15:00 15:15 **Case Study:** When Lived Experience Shapes Science — A Partnership Case Study

Dr Fiona Brown, George Kiosoglou

15:15 15:45 **Panel Discussion and Q&A:** George Kiosoglou, Anna Steiner, Kat Morris, Tanya Doecke, Ken Young

15:45	16:15	Afternoon Tea & Trade Display	HALL M
-------	-------	-------------------------------	--------

16:15	18:00	SESSION 9 - Myelodysplastic Syndrome and Acute Myeloid Leukaemia	sponsored by:  HALL L
-------	-------	--	--

CHAIRS: Dr Victoria Ling and A/Prof Lev Kats

16:15 16:45 **INVITED SPEAKER:** Predisposition gene discovery for blood cancer, bone marrow failure and related conditions, **Professor Hamish Scott**, SA Pathology

16:45 17:15 **INVITED SPEAKER:** Single cell multiomics reveal clonal and functional dynamics of MDS stem/progenitor cells during hypomethylating therapy, **Dr Julie Thoms**, University of New South Wales

17:15 17:35 105 USP48 Loss Increase Sensitivity to Hypomethylating Agents in Acute Myeloid Leukemia, Constanze Schneider, Dana Farber Institute

17:35 17:45 104 Novel immunotherapy for TET2-mutated CMML, Professor Daniel Thomas, SAHMRI

17:45 18:00 63 Mechanistic insights into how venetoclax-based therapy durably eradicates NPM1 mutated clones in acute myeloid leukaemia, Dr Fiona Brown, Walter and Eliza Hall Institute

18:00 19:00 *Break*

19:00	Late	Social Dinner	sponsored by:  The Hospital Research Foundation Group	WINE CENTRE
-------	------	---------------	---	-------------

PROGRAM

Start Time	End Time	Paper #	Room
WEDNESDAY 4 MARCH 2026			
08:00	15:30	Registration Opens	FOYER M
08:00	15:30	Exhibition & Poster Displays Open	HALL M
08:00	14:00	Speaker Support	Room L2
08:00	08:45	Meet-the-Editors Session Professor Andrew Roberts - Editor-in-Chief of Blood Professor Jan Cools - Editor-in-Chief of HemaSphere	<i>sponsored by:</i>  HemaSphere
9:00	11:00	SESSION 10 - Acute Myeloid Leukaemia	HALL L
		<i>CHAIRS: Prof Stefan Bohlander and Dr Fiona Brown</i>	
9:00	9:20	INVITED SPEAKER: Using MRD to make treatment decisions in AML Dr Jad Othman (Clinical Spotlight), Royal North Shore Hospital	
9:20	9:50	INVITED SPEAKER: Targeting epigenetic regulatory complexes in SETBP1-mutant myeloid malignancies, Associate Professor Julia Maxson , Knight Cancer Institute	
9:50	10:20	INVITED SPEAKER: Dnmt3a mutations regulate disease progression and response to treatment in acute myeloid leukaemia, Professor Steven Lane , QIMR Berghofer	
10:20	10:35	57 Targeting PAR1 in aggressive blood cancer: A novel strategy to eradicate leukemic stem cells, Dr Nunki Hassan, University of Sydney	
10:35	10:50	82 Cu-Later AML: Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia, Dr Alexander Lewis, Peter MacCallum Cancer Centre	
10:50	11:00	97 Real-World Outcomes of Older Adults with Acute Myeloid Leukaemia Before and During the Venetoclax Era: An Australasian Leukaemia and Lymphoma Group (ALLG) National Blood Cancer Registry (NBCR) Study, Dr Patrick Lawrence, Princess Alexandra Hospital	
11:00	11:30	Morning Tea & Trade Display	HALL M
11:30	13:00	SESSION 11 - Epigenetics/Gene Regulation in Blood Cancer	HALL L
		<i>CHAIRS: Dr Teresa Sadras and Dr Chloe Thompson-Peach</i>	
11:30	12:00	INVITED SPEAKER: Ectopic BCL11B: From chromatin mis-regulation to therapeutic vulnerability Dr Lindsey Montefiori , St. Jude Children's Research Hospital	
12:00	12:30	INVITED SPEAKER: Coordinated targeting of epigenetic and transcriptional networks to exploit blood cancer dependency on dysregulated gene expression, Dr Jennifer Devlin , Peter MacCallum Cancer Centre	
12:30	12:45	21 Drug-induced epigenetic memory enables rational and effective sequential therapy in Acute Myeloid Leukaemia, Dr Omer Gilan, Monash University	
12:45	13:00	72 Mapping the AKR1C3 cis-regulome in acute lymphoblastic leukaemia to enhance targeted therapy with a new AKR1C3-activated prodrug, Dr Hansen Kosasih, Children's Cancer Institute	
13:00	14:00	Lunch & Trade Display	HALL M
14:00	15:50	SESSION 12 - Targeting High-risk Paediatric Leukaemia	HALL L
		<i>CHAIRS: Dr Diane Hanna and Dr Matthew Witkowski</i>	
14:00	14:20	INVITED SPEAKER: Targeted therapies for infants with acute lymphoblastic leukaemia Professor Rishi Kotecha (Clinical Spotlight), Perth Children's Hospital	
14:20	14:50	INVITED SPEAKER: Ushering JMML into the molecular era Dr Elliott Stieglitz , UCSF Benioff Children's Hospitals	
14:50	15:05	14 Menin a therapeutic target in non-KMT2Ar T-ALL? , Dr. Steven Goossens, Ghent University	
15:05	15:20	81 Efficacy of novel targeted therapies in Down syndrome acute lymphoid leukaemia, Miss Kunjal Panchal, The Kids Research Institute Australia	
15:20	15:50	Conference Closing & Awards Presentation	
15:50		Close	

POSTER DISPLAYS

Posters will be displayed from Monday 2 March to Wednesday 4 March.

All poster presenters should be alongside their poster during the allocated poster session and during schedule breaktimes where possible.

Paper #	Poster #	Theme	
11	P1	Acute Lymphoblastic Leukaemia	Therapy-induced mechanisms of adaptive resistance in T-cell Acute Lymphoblastic Leukaemia, Johnathon Lucas, University of Manitoba
12	P2	Acute Lymphoblastic Leukaemia	Pharmacological inhibition of sclerostin protects bone from B-cell acute lymphoblastic leukaemia-mediated destruction, Dr Vincent Kuek, The Kids Research Institute Australia
34	P3	Acute Lymphoblastic Leukaemia	Pre-clinical assessment of dinaciclib in treatment of high-risk infant B-cell acute lymphoblastic leukaemia, Dr Sung Chiu, The Kids Research Institute Of Australia
46	P4	Acute Lymphoblastic Leukaemia	Co-targeting BCL-2 and MCL-1 (Via CDK9) in pre-clinical models of high-risk Acute Lymphoblastic Leukaemia (ALL), Dr Donia Moujalled, Walter And Eliza Hall Institute
48	P5	Acute Lymphoblastic Leukaemia	SOX11 induces $\gamma\delta$ T-cell differentiation and synergizes with MYCN to drive LMO2 $\gamma\delta$ -like T-cell acute lymphoblastic leukemia, Dr Tim Pieters, Ghent University
49	P6	Acute Lymphoblastic Leukaemia	Efficacy of NAMPT inhibition in Down Syndrome-associated Acute Lymphoblastic Leukaemia, Miss Amelia Dyton, The Kids Research Institute Australia
83	P7	Acute Lymphoblastic Leukaemia	Comprehensive Clarity: How the ZERO Childhood Cancer sequencing program is driving deeper understanding of Acute Lymphoblastic Leukemia biology and prognosis., Miss Kimberly Dias, Children's Cancer Institute
7	P8	Acute Lymphoblastic Leukaemia	Decoding the aberrant IL-7/STAT5 axis driving therapy resistance in T-ALL, Mr Johnathon Lucas, University of Manitoba
18	P9	Acute Lymphoblastic Leukaemia	Extracellular vesicles induce leukaemogenesis in cytokine dependent parental Ba/F3 cells via horizontal transfer of CRLF2 p.F232C genomic material, Mr Maxim Buckley, Adelaide University
54	P10	Acute Lymphoblastic Leukaemia	Harnessing the gut-brain axis to reduce CNS toxicity in acute lymphoblastic leukaemia , Dr Elyse Page, SAHMRI
56	P11	Acute Lymphoblastic Leukaemia	DUX4 Detective: Interrogating the DUX4 rearranged subtype of B-ALL for a molecular lead, Mr Thomas McGovern, SAHMRI
80	P12	Acute Lymphoblastic Leukaemia	Modelling the CNS-niche in vitro to investigate therapeutic vulnerabilities in acute lymphoblastic leukaemia, Mr Luke Quinlan, South Australian Health And Medical Research Institute
75	P13	Acute Lymphoblastic Leukaemia	Investigating TKI Resistance Using Novel CRISPR-generated NUP214::ABL1 and SFPQ::ABL1 Ph-like ALL Models, Mrs Shengjie Wang, Olivia Newton John Cancer Research Institute
70	P14	Acute Lymphoblastic Leukaemia	Distinct signalling networks and drug responses of JAK2 and NRAS mutant subclones in CRLF2-positive B-ALL, Ms Kaitlyn Kew, Olivia Newton John Cancer Research Institute
66	P15	Acute Lymphoblastic Leukaemia	New hope for the universally fatal TCF3::HLF-positive paediatric B-cell acute lymphoblastic leukaemia, Ms Zahra Sheybani, Children's Cancer Institute
69	P16	Acute Lymphoblastic Leukaemia	New mouse model systems to study oncogenic fusions in high-risk childhood acute lymphoblastic leukaemia, Ms Kristy Yeats, Children's Cancer Institute
15	P17	Acute Lymphoblastic Leukaemia	Improving Genomic Alignment Accuracy and Variant Detection for Acute Lymphoblastic Leukemia Patients: A Pan-Genome Graph Approach, Ashlee Thomson, Sahnri
61	P18	Acute Lymphoblastic Leukaemia	The Short-Chain Fatty Acid Butyrate; a novel microbe-derived defence against Acute Lymphoblastic Leukaemia. , Cate Cheney, SAHMRI
73	P19	Acute Lymphoblastic Leukaemia	Development of a novel microbiome screening method to predict late-effects risk in paediatric ALL survivors. , Joyce Mugabushaka, SAHMRI

Paper #	Poster #	Theme	
50	P20	Acute Myeloid Leukaemia	Targeting CD93 signalling to overcome venetoclax resistance in acute myeloid leukemia, A/Prof Jason Powell, Centre for Cancer Biology
19	P21	Acute Myeloid Leukaemia	DNMT3A mutation-driven chemoresistance arises from transcriptionally-primed quiescent leukemia stem cells in NPM1c-FLT3ITD AML, Dr Paniz Tavakoli Shirazi, Qimr Berghofer
22	P22	Acute Myeloid Leukaemia	Multi-Omic Profiling to Inform AML Treatment Strategies, Dr Heather Murray, The University of Newcastle
38	P23	Acute Myeloid Leukaemia	Destroying Leukaemia Stem Cells with inhibition of Aryl Hydrocarbon Receptor, Dr Alyona Oryshchuk, University of Auckland Waipapa Taumata Rau
99	P24	Acute Myeloid Leukaemia	In vivo CRISPR activation screens identify novel tumour drivers of acute erythroid leukaemia, Dr Yexuan Deng, Walter And Eliza Hall Institute of Medical Research
10	P25	Acute Myeloid Leukaemia	Investigating therapeutically targetable mechanisms of SNAI1-driven Acute Myeloid Leukaemia, Miss Lynda Truong, Hudson Institute of Medical Research
13	P26	Acute Myeloid Leukaemia	Investigating the role of colony-stimulating factor 3 receptor (CSF3R) and runt-related transcription factor 1 (RUNX1) in the progression of acute myeloid leukemia (AML), Miss Tarindhi Ratnayake, Deakin University
27	P27	Acute Myeloid Leukaemia	Restoring sensitivity to venetoclax in AML through inhibition of DNA-PK-mediated DNA repair , Miss Maddison Chambers, University of Newcastle
47	P28	Acute Myeloid Leukaemia	Induction of interferon signalling dictates Menin inhibitor efficacy in NPM1 mutant AML, Mr Joseph Cefai, Peter MacCallum Cancer Centre
26	P29	Acute Myeloid Leukaemia	Microenvironment-guided functional profiling of venetoclax-hypomethylating agent sensitivity and resistance in acute myeloid leukemia, Mr. Yohannes Kelifa Emiru, University of Newcastle
41	P30	Acute Myeloid Leukaemia	Mutational analysis of DDX41 in myelodysplastic syndromes and acute myeloid leukaemia, Mr. Duy Nguyen, The University of Auckland
87	P31	Acute Myeloid Leukaemia	RAS pathway-mutant acute myeloid leukaemia is resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF antibody therapy, Kelly Lim, Adelaide University
98	P32	Acute Myeloid Leukaemia	Engineered humanized stem cell model of clonal haematopoiesis with TP53 mutation, Mr. Hossein Anani, Adelaide University
106	P33	Acute Myeloid Leukaemia	Single-Cell MRD Assessment in AML Reveals Clonal Diversity and Genotype-Phenotype Discordance Missed by Bulk Methods, Mission Bio,
55	P34	Chronic Lymphocytic Leukaemia	Dual mTORC1/2 inhibition by Torin 2 induces cytotoxic and cytostatic effects in in vitro models of chronic lymphocytic leukaemia (CLL), Dr Lauren Thurgood, Flinders University
59	P35	Chronic Lymphocytic Leukaemia	Proteomic-led drug discovery reveals lipid and non-canonical PI3K pathways as therapeutic targets in chronic lymphocytic leukaemia, Dr Lauren Thurgood, Flinders University
92	P36	Chronic Lymphocytic Leukaemia	Clinical significance of endogenous DNA modifications as biomarkers in chronic lymphocytic leukemia, Dr Daniel Gackowski, Nicolaus Copernicus University In Toruń
5	P37	Chronic Lymphocytic Leukaemia	Developing a novel lipid-based imaging tool for the surveillance of chronic lymphocytic leukemia, Miss Olivia Burling, Flinders University
31	P38	Epigenetics	Stag2 cohesin loss promotes myelodysplasia and leukaemia through chromatin regulation, Dr Jane Xu, Columbia University Irving Medical Center
64	P39	Epigenetics	Unravelling the epigenetic drivers of CHIP – MDS/CMML – AML progression through novel Methylation-Sensitive Regulatory Elements, Dr Mahmoud Bassal, Beth Israel Deaconess Medical Center
74	P40	Epigenetics	Targeting Cohesin Mutations in Leukemia to identify druggable avenues., Dr Jisha Antony, University of Otago
94	P41	Epigenetics	Profiling of RNA modifications in patients with chronic lymphocytic leukemia: Insights into potential biomarkers., Dr Marta Starczak, Nicolaus Copernicus University In Toruń
95	P42	Epigenetics	Examining the efficacy of targeting mutant TET2 in AML, Ms Leeann Desouza, Centre For Cancer Biology, University of South Australia

Paper #	Poster #	Theme	
91	P43	Genomics	Australian Familial Haematological Conditions Study – Exploring the utility of exome re-analysis and long-read genome sequencing in molecular diagnosis of inherited bone marrow failure and blood cancer predisposition syndromes, Dr Leanne de Kock, Adelaide University
32	P44	Genomics	Addressing index hopping as a sensitivity-limiting factor in NGS-based MRD detection in AML, Miss Mariam Alhilali, The University of Auckland
79	P45	Genomics	Hidden Drivers in Non-Coding Regions: UTR Alterations Promote Immune Checkpoint Dysregulation and Oncogenic Activity, Ms Fatimah Jalud, Olivia Newton John Cancer Research Institute
86	P46	Genomics	Analysis of population and disease databases expands the genotypic and phenotypic landscape of ERG Deficiency Syndrome to include cardiovascular dysfunction, Ms Jiarna Zerella, Centre for Cancer Biology, CCB
35	P47	Genomics	Exploiting the molecular crosstalk between RNA Polymerase II and epigenetic regulators - novel therapeutic opportunities in leukaemia/blood cancer, Ms. Shenali A. Ranasinghe, Peter MacCallum Cancer Centre
24	P48	Genomics	Investigating the role of SAGA in Regulating RNA Polymerase-II-Dependent Transcription in Cancer, Yvonne Daniel, Peter MacCallum Cancer Centre, Parkville, VIC
90	P49	Myelodysplastic Syndrome	Ascorbate downregulates proinflammatory cytokines in a humanized model of TET2 clonal haematopoiesis and in patients with TET2 mutant chronic myelomonocytic leukaemia, Professor Daniel Thomas, SAHMRI, Adelaide University
107	P50	Myelodysplastic Syndrome	Therapeutic Silencing of Tmprss6 Reduces Iron-Induced Inflammation and Prolongs Survival in MDS mice, Dr Jim Vadolas, Hudson Institute of Medical Research
20	P51	Myeloma	Polyamine blocking therapy to limit multiple myeloma plasma cell growth, Dr Jacqueline Noll, Adelaide University
28	P52	Myeloma	Defining the non-catalytic role of NSD2 in t(4;14) Multiple Myeloma, Mr Joshua King, Peter MacCallum Cancer Centre
40	P53	Myeloma	Elevated desmoglein-2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high-risk cytogenetics and a distinct gene expression profile, Dr Barbara McClure, Centre for Cancer Biology, Adelaide University
42	P54	Myeloma	Using Olink proteomics and single RNA sequencing to discover proteins that distinguish MGUS and multiple myeloma., Dr Melissa Cantley, Adelaide University
44	P55	Myeloma	Overcoming Cereblon species specificity: development of an IMiD®-sensitive C57BL/KaLwRij murine model of multiple myeloma via CrbnI391V expression, Dr Emma Cheney, Adelaide University
45	P56	Myeloma	The myeloma drug bortezomib induces gastrointestinal toxicity and peripheral neuropathy in mice that is influenced by the gut microbiota, Dr Krzysztof Mroziak, Adelaide University
16	P57	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	Investigating the molecular basis of mRNA stability in leukaemia, Dr Mary-Jane Tsang, Peter MacCallum Cancer Centre
77	P58	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	The role of Copy Number Aberrations in MPN leukaemic transformation driven by p53-loss, Dr Megan Bywater, QIMR Berghofer
67	P59	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	RUNX1 and beyond: genetic mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukaemia, Miss Zuhail Naderi, South Australian Health And Medical Research Institute
8	P60	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	Identification of common factors driving myelofibrosis, PhD Alban Johansson, QIMR Berghofer
6	P61	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	JAK2V617F Directly Impairs NK and T Cell Maturation While the MPN Microenvironment Drives Immune Exhaustion, Mariana Medeiros, University of Sao Paulo/QIMR Berghofer
33	P62	Myeloproliferative Neoplasms including Chronic Myeloid Leukaemia	Genomic complexity and adaptive alterations underpin drug resistance in myeloid blast crisis chronic myeloid leukaemia cell lines , Adelina Fernandes, Adelaide University

Paper #	Poster #	Theme	
23	P63	New Therapeutic Approaches	The molecular mechanisms of CDK10 and CDK20 in targeting transcription cycles dysregulated in leukaemia, Dr Salla Kyheröinen, Peter MacCallum Cancer Centre
39	P64	New Therapeutic Approaches	Dysregulated transcription directs APOBEC mutagenesis through R-loop formation in multiple myeloma, Dr. Nenad Bartonicek, Peter MacCallum Cancer Centre
36	P65	New Therapeutic Approaches	TR-107 has cytotoxic and anti-proliferative effects against Diffuse Large B-Cell Lymphoma through downregulation of key mitochondrial pathways., Mr Benjamin Davies, Flinders University
52	P66	New Therapeutic Approaches	Inhibition of nicotinamide metabolism by the novel NAMPT inhibitor OT-82 potentiates venetoclax in paediatric and adult acute myeloid leukaemia models, Mawar Karsa, Children's Cancer Institute
60	P67	New Therapeutic Approaches	Differential sensitivity of in vitro models of KMT2A-rearranged infant acute lymphoblastic leukaemia to menin inhibitors, Mr Stephen Dymock, The Kids Research Institute Australia
65	P68	Paediatric Leukaemia	Venetoclax-based therapy as a bridge to haematopoietic stem cell transplantation in relapsed or refractory paediatric acute leukaemia, Dr Katherine Colman, WEHI
101	P69	Paediatric Leukaemia	PICALM::MLLT10 in Childhood non-Down Syndrome Acute Megakaryoblastic Leukaemia, Dr Katherine Colman, The Royal Children's Hospital
102	P70	Paediatric Leukaemia	Uncovering Germline Structural Variants in Paediatric Acute Myeloid Leukaemia, Luis Arriola-Martinez, Adelaide University
68	P71	Stem Cells and Microenvironment	Bioengineered Adult Human Endothelial Cell Derived Haematopoietic Stem Cells Re-establish Haematopoiesis in Failed Bone Marrow., Dr Vashe Chandrakanthan, Adelaide University
93	P72	Stem Cells and Microenvironment	Modelling Disease Manifestation in Hereditary Haematological Malignancies, Dr Parvathy Venugopal, Centre For Cancer Biology